Risk reduction of falls and fractures, reduction of back pain and safety in elderly high risk patients receiving combined therapy with alfacalcidol and alendronate: A prospective study

Arzneimittel-Forschung/Drug Research

Volumn 61, Issue 1, 2011, Pages 40-54

  Schacht, Erich ^a   Ringe, Johann D ^b  

^a ZORG Zurich Osteoporosis Research Group   (Switzerland)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Alendronate; Alfacalcidol; Back pain; Elderly; Falls; Fractures; Muscle; Osteoporosis

Indexed keywords

ALENDRONIC ACID; ALENDRONIC ACID PLUS ALFACALCIDOL; BISPHOSPHONIC ACID DERIVATIVE; COLECALCIFEROL DERIVATIVE; TEVABONE; UNCLASSIFIED DRUG;

ABDOMINAL DISCOMFORT; AGED; ARTICLE; ASTHENIA; BACKACHE; BODY MASS; COHORT ANALYSIS; CONSTIPATION; CORTICOSTEROID INDUCED OSTEOPOROSIS; CREATININE CLEARANCE; DIARRHEA; DIZZINESS; DRUG SAFETY; DRUG WITHDRAWAL; FALLING; FEMALE; FRACTURE; GERMANY; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MUSCLE FUNCTION; MUSCLE STRENGTH; NAUSEA; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PERFORMANCE; POSTMENOPAUSE OSTEOPOROSIS; PROSPECTIVE STUDY; PRURITUS; RISK REDUCTION; TREATMENT OUTCOME; UPPER ABDOMINAL PAIN; VERTEBRA FRACTURE; VISUAL ANALOG SCALE; VOMITING;

EID: 79951868498     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296166     Document Type: Article

References (124)

1. Youm T, Koval KJ, Kummer FJ, Zuckerman JD. Do all hip fractures result from a fall? AmJ Orthop. 1999;28:190-4.
2. Kaptoge S, Benevolenskaya LI, Bhalla AK, Cannata JB, Boonen S, Falch JA, et al. Low BMD is less predictive than reported falls for limb fractures in women across Europe : results from the European Prospective Osteoporosis Study. Bone. 2005;36:387-97.
3. Runge M, Schacht E. Multifactorial pathogenesis of falls as a basis for multifactorial interventions. J Muscoloskelet Neuronal Interact . 2005;5(2):127-34. (Pubitemid 41419018)
4. Järvinen TLN, Sievanen H, Khan KM, Heinonem A, Kannis P. Shifting the focus in fracture prevention from osteoporosis to falls. Br Med J. 2008;336:124-6. (Pubitemid 351211962)
5. Birge SJ. Osteoporotic fractures: a brain or bone disease? Curr Osteoporos Rep. 2008;6:57-61.
6. Tuohimaa P, Keisala T, Minasyan A, Cachat J, Kalueff A. Vitamin D, nervous system and aging. Psychoneuroendocrinology. 2009;34S:S278-86.
7. Ito M, Azuma Y, Takagi H, Komoriya K, Ohta T, Kawaguchi H. Curative effect of combined treatment with alendronate and 1a-hydroxyvitamin D3 on bone loss by ovariectomy in aged rats. Jpn J Pharmacol. 2002;89:255-66.
8. Erben RG, Mosekilde L, Thomsen JS, Weber K, Stahr K, Leyshon A, et al. Prevention of bone loss in ovariectomized rats by combined treatment with risedronate and 1a-25-dihydroxyvitamin D3. Bone Miner Res. 2002;17(8):1498-511. (Pubitemid 34803833)
9. Shiraishi A, Ito M, Hayakawa N, Kubota N, Imai N. Combination therapy with alfacalcidol and risedronate at their sub-therapeutic doses can additively improve bone dynamics in ovariectomized rat model of osteoporosis. J Bone Miner Res. 2004;19 (Suppl 1):180.
10. Schacht E, Dukas L, Richy F. Combined therapies in osteoporosis: bisphosphonates and vitamin D-hormone analogs. J Muskoloskelet Neuronal Interact . 2007;7(2):174-84. (Pubitemid 47249008)
11. Ringe JD, Farahmand P, Schacht E, Rozehnal A. Superiority of a combined treatment of alendronate and alfacalcidol compared to the combination of alendronate and plain vitamin D or alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-trial). Rheumatol Int. 2007;27:425-34. (Pubitemid 46294994)
12. Ringe JD, Schacht E. Improving the outcome of established therapies for osteoporosis by adding the active Dhormone analog alfacalcidol. Rheumatol Int . 2007;28:103-11. (Pubitemid 350105872)
13. Felsenberg D, Bock O, Boerst H, Armbrecht G, Beller G, Degner C, et al. Additive impact of alfacalcidol on bone mineral density and bone strength in alendronate treated postmenopausal women with reduced bone mass. Accepted for publication in: J Musculoskelet Neuronal Interact.
14. Nevitt MC, Thompson DE, Black DM, Rubin SR, Ensrud K, Yates AJ, et al. Effect of alendronate on limited-activity days and bed-disability days caused by back pain in post-menopausal women with existing vertebral fractures. Arch Intern Med. 2000;160:77-85. (Pubitemid 30040976)
15. Iwamoto J, Takeda T, Sato Y, Uzawa M. Effects of alendronate on metacarpal and lumbar bone mineral density, bone resorption and chronic back pain in postmenopausal women with osteoporosis. Clin Rheumatol. 2004;23:383-9. (Pubitemid 39386432)
16. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serumcreatinine. Nephron. 1976;16(1):31-41.
17. American Geriatrics Society, British Geriatrics Society and American Academy of Orthopaedic Surgeons Panel on Falls Prevention. J AmGeriatr Soc. 2001;49:664-72.
18. DVO Leitlinie. Osteoporose bei postmenopausalen Frauen DVO-Leitlinie 2003 (serial online); (46 screens). Available from: http://www.lutherhaus.de/osteo. leitlinien-dvo/
19. Rodan GA, Seedor JG, Balena R. Preclinical pharmacology of alendronate. Osteoporosis Int. 1993;3:7-12. (Pubitemid 23339618)
20. Podsialdo D, Richardson S. The timed up and go test: a test of basic functional mobility for frail elderly persons. J AmGeriatr Soc. 1991;39 (2):142-8.
21. Shumway-Cook A, Brauer S, Woollacott M. Predicting the probability for falls in community-dwelling older adults using the timed up & go test. Phys Ther. 2000;80:896-903.
22. Bischoff HA, Stahelin HB, Monsch AU, Iverson M, Weyh A, von Dechend M, et al. Identifying a cut-off point for normal mobility: a comparison of the timed "up and go" test in community dwelling and institutionalized elderly women. Age Ageing. 2003;32;315-20.
23. Zhu K, Devine A, Prince R. Neuromuscular function and bone density as independent predictors of fracture in older women: A 10-year longitudinal study. Bone. 2008;43:S26-37.
24. Guralnik JM, Ferrucci L, Simonsick EM, Salive ME, Wallace RB. Lower-extremity function in persons over the age of 70 years as a predictor of subsequent disability. N Engl J Med. 1995;332:556-61.
25. Gill TM, Williams CS, Tinetti ME. Assessing risk for the onset of functional dependence among older adults:the role of physical performance. J Am Geriatr Soc. 1995;43:603-9.
26. Wewers ME, Lowe NK. A critical review of visual analogue scales in the measurement of clinical phenomena. Res Nurs Health. 1990;13 (4):227-36.
27. Cummings SR, Nevitt MC, Browner WS, Stone K, Fox KM, Ensrud KE, et al. Study of Osteoporotic Fractures Research Group. Risk factors for hip fracture in white women. N Engl J Med. 1995;332:767-73.
28. Black DM, Cummings SR, Karpf DB, Cauly JA, Thompson DE, Nevitt MC, et al., Fracture Intervention Trial Research Group. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 1996;348:1535-41.
29. Hodgson SF, Watts NB, AACE Osteoporosis Task Force. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the prevention and treatment of postmenopausal osteoporosis - 2001 edition, with selected updates for 2003. Endocr Pract . 2003;9(6):544-64.
30. Russell RGG, Watts NB, Ebetineo FH, Rogers MJ:Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. 2008;19:733-59.
31. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev. 1998;19:80-100. (Pubitemid 29122075)
32. Russell RG, Rogers MJ. Bisphosphonates:from the laboratory to the clinic and back again. Bone. 1999;25:97-106. (Pubitemid 29322070)
33. Uusi-Rasi K, Kannus P, Cheng S, Sievanen H, Pasanen M, Heinonen A, et al. Effect of alendronate and exercise on bone and physical performance of postmenopausal women: a randomized controlled trial. Bone. 2003;33:132-43. (Pubitemid 36952695)
34. Wong M, Lord S, Lu Y, Lakshmanan M, Scheele W. Raloxifene does not affect neuromuscular related risk factors for falling or the incidence of falls in postmonopausal women with osteoporosis. J AmGeriatr Soc. 2000;48:S44 (P134).
35. McClung MR, Geusens P,Miller PD, Zippel H, Bensen WG, Roux C, et al. Effect of Risedronate on the risk of hip fracture in elderly women.NEngl J Med. 2001;344:333-40.
36. Papadimitropoulos E, Wells G, Shea B, Gillespie W, Weaver B, Zytaruk N, et al. Osteoporosis Methodology Group, Osteoporosis Research Advisory Group. VIII: meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women. Endocrin Rev. 2002;23:560-9.
37. [37[ Richy F, Ethgen O, Bruyere O, Reginster JY. Efficacy of alphacalcidol and calcitriol in primary and corticosteroidinduced osteoporosis: a meta-analysis of their effects on bone mineral densitiy and fracture rate. Osteoporos Int. 2004;15:301-10.
38. O'Donnell S, Moher D, Thomas K, Hanley DA, Cranney A. Systematic review of the benefits and harms of calcitriol and alfacalcidol for fractures and falls. J Bone Mineral Metab. 2008;26:531-42.
39. Richy F, Schacht E, Bruyere O, Ethgen O, Gourlay M, Reginster JY. Vitamin D analogs versus native vitamin D in preventing bone loss and osteoporosis-related fractures - a comparative meta-analysis. Calcif Tissue Int. 2005;76:176-86. (Pubitemid 41557146)
40. Nuti R, Bianchi G, Brandi ML, Caudarella R, D'Erasmo E, Fiore C, et al. Superiority of alfacalcidol compared to vitamin D plus calcium in lumbar bone mineral density in postmenopausal osteoporosis. Rheumatol Int. 2006;26:445-53.
41. Dukas L, Bischoff HA, Lindpainter LS, Schacht E, Birkner-Binder D, Damm TN, et al. Alfacalcidol reduces the number of fallers in a community-dwelling elderly population with a minimumcalcium intake of more than 500 mg daily. J AmGeriatr Soc. 2004;52:230-6. (Pubitemid 38233485)
42. Gallagher JC. The effects of Calcitriol on falls and fractures and physical performance tests. J Steroid Biochem Mol Biol. 2004;89-90:497-501. (Pubitemid 38844337)
43. Dukas L, Schacht E, Mazor Z, Staehelin HB. Treatment with alfacalcidol in elderly people significantly decreases the high risk of falls associated with a low creatinine clearance of < 65 ml/min. Osteoporos Int . 2005;16(2):198-203. (Pubitemid 40193208)
44. Gallagher JC, Rapuri PB, Smith LM. An age related decrease in creatinine clearance is associated with an increase in number of falls in untreated women but not in women receiving calcitriol. J Clin Endocrinol Metab. 2007;92:51-8. (Pubitemid 46067508)
45. Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, Staehelin HB, Bazemore MG, Zee RY, et al. Effect of vitamin D on falls. J AmMed Assoc. 2004;291(16):1999-2006.
46. Richy F, Dukas L, Schacht E. Differential effects of D-hormone analogs and native vitamin D on the risk of falls:A comparative meta-analysis. Calcif Tissue Int . 2008;82:102-7.
47. Lau KHW, Baylink DJ. Vitamin D Therapy of osteoporosis: plain vitamin D therapy versus active vitamin D analog (D-hormone) therapy. Calcif Tissue Int . 1999;65:295-306. (Pubitemid 29471011)
48. Ringe JD, Schacht E. Prevention and therapy of osteoporosis: The roles of plain vitamin D and alfacalcidol. Rheumatol Int. 2004; 24:189-97. (Pubitemid 39062487)
49. Schacht E. Reduction of falls and osteoporotic fractures: Plain vitamin D or D-hormone analogs? Geriatr Gerontol Int. 2008;8 (Suppl. 1):16-25.
50. Schwartz AV, Bauer DC, Cummings SR, Cauley JA, Ensrud KE, Palermo L, et al. Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fractures: the FLEX trial. J Bone Mineral Res. 2010;25(5):976-82.
51. Dollery C, editor. Alfacalcidol - therapeutic drugs. 2nd ed. Edinburgh: Churchill Livingstone; 1999. p. A75-79.
52. Francis RM, Boyle IT, Moniz C, Sucliffe AM, Davis BS, Benstall GH, et al. A comparison of the effects of alfacalcidol treatment and vitamin D supplementation on calcium absorption in elderly women with vertebral fractures. Osteoporos Int. 1996;6:284-90. (Pubitemid 26280821)
53. Schacht E. Rationale for treatment of involutional osteoporosis in women and for prevention and treatment of corticosteroid-induced osteoporosis with Alfacalcidol. Calcif Tissue Int. 1999;65:317-27. (Pubitemid 29471014)
54. Ikeda K, Ogata E. The effect of vitamin D on osteoblasts and osteoclasts. Curr Opin Orthop. 1999;10:339-43.
55. Shiraishi A, Higashi S, Masaki T, Saito M, Ito M, Ikeda T, et al. A comparison of alfacalcidol and menatetrenone for the treatment of bone loss in an ovariectomized rat model of osteoporosis. Calcif Tissue Int. 2002;71:69-79. (Pubitemid 36934779)
56. Erben R. G. Vitamin D analogs and bone. J Musculoskel Neuronal Interact. 2001;2(1):59-69.
57. Van Driel M, Pols HA, van Leeuwen JP. Osteoblast differentiation and control by vitamin D and vitamin D metabolites. Curr Pharm Des. 2004;10(21):2535-55. (Pubitemid 39004077)
58. 3 acts as a bone-forming agent in the hormone-independent senescence-accelerated mouse (SAMP/ 6). Am J Physiol Endocrinol Metab. 2005;288(4):E723-30.
59. Sorensen OH, Lund BI, Saltin B, Lund BJ, Andersen RB, Hjorth L, et al. Myopathy in bone loss of aging: Improvement by treatment with 1-alpha-hydroxycholecalciferol and calcium. Clin Sci. 1979;56(2):157-61. (Pubitemid 10072237)
60. Boland R. Role of Vitamin D in skeletal muscle function. Endocr Rev. 1986;7:434-47.
61. Verhaar HJJ, Samson MM, Jansen PAF, de Vreede PL, Manten JW, Duursma SA. Muscle strength, functional mobility and vitamin D in older women. Aging Clin Exp Res. 2000;12;455-60. (Pubitemid 32095602)
62. Endo, I, Inoue D, Mitsui T, Umaki Y, Akaike M, Yoshizawa T, et al. Deletion of vitamin D receptor gene in mice results in abnormal skeletal muscle development with deregulated expression of myoregulatory transcription factors. Endocrinology. 2003;144(12):5138-44. (Pubitemid 37476038)
63. Peacock M, Heyburn PJ. Effect of vitamin D3 metabolites on proximal muscle weakness. Calcif Tissue Res. 1977;24 (Suppl.):R20.
64. Neveu I, Naveilhan P, Jehan F, Baudet C, Wion D, DeLuca HF, et al. 1,25-Dihydroxyvitamin D 3 regulates the synthesis of nerve growth factor in primary cultures of glial cells. Mol Brain Res. 1994;24:70-6.
65. Carswell S. Vitamin D in the nervous dystem: actions and therapeutic potential. Chapter 71. In: Feldman D, Glorieux FH, Pike JW, editors. Vitamin D. San Diego: Academic Press; 1997. p. 1197-1211.
66. Koike T, Okawa T, Wada M, Kita T, Takaoka K. Effects of a long-term alfacalcidol or calcitonin administration on body sway in Japanese elderly women. J Bone Miner Res. 2003;18(S2):S168.
67. Miya K, Morimoto S, Fukuo K, Imanaka S, Shiraishi T, Yamamato H, et al. Cognitive function and calcium related factors in elderly female subjects. Nippon Ronen Igakkai Zasshi. 1991;28:34-9.
68. DeLuca HF, Cantorna MT. Vitamin D. Its Role and uses in immunology. FASEB J. 2001;15:2579-85.
69. Mathieu C, Adorini L. The coming of age of 1.25-dihydroxyvitamin D3 analogs as immunomodulatory agents. Trends Mol Med. 2002;8:174-9. (Pubitemid 34297090)
70. Inanir A, Ozoran K, Tutkak H, Mermerci B. The effects of calcitriol therapy on serum interleukin-1, interleukin-6 and tumour necrosis factor-alpha concentrations in postmenopausal patients with osteoporosis. J Int Med Res. 2004;32:570-82. (Pubitemid 39561761)
71. Scharla SH, Schacht E, Lempert UG. Alfacalcidol vs plain vitamin D in inflammation induced bone loss. J Rheumatol. 2005;32(Suppl):26-32. (Pubitemid 41324841)
72. Andjelkovic Z, Vojinovic J, Pejnovic N, Popovic M, Dujic A, Mitrovic D, et al. Disease modifying and immunomodulatory effects of high dose 1a (OH) D3 in rheumatoid arthritis patients. Clin Exp Rheumatol. 1999;17:453-6. (Pubitemid 29343630)
73. Verstuyf A, Carmeliet G, Bouillon R, Mathieu C. Vitamin D: a pleiotropic hormone. Kidney Int. Epub 2010 Feb 24. doi:10.1038/ki.2010.17.
74. FDA, Food and Drug Administration 2004. Draft guidance for industry in the preclinical and clinical evaluation of agents used in the prevention and treatment of postmenopausal osteoporosis: request for comments; 69 ed. p. 6673-6675.
75. Shiraishi A, Higashi S, Ohkawa H, Kubodera N, Hirasawa T, Ezawa I, et al. The advantage of alfacalcidol over vitamin D in the treatment of osteoporosis. Calcif Tissue Int. 1999;65:311-6. (Pubitemid 29471013)
76. Shiraishi A, Takeda S, Masaki T, Higuchi Y, Uchiyama Y, Kubodera N, et al. Alfacalcidol inhibits bone resorption and stimulates formation in an ovariectomized rat model of osteoporosis - distinct actions from estrogen. J Bone Miner Res. 2000;15:770-9. (Pubitemid 30174031)
77. Shibata T, Shiraishi A, Sato T, Masaki T, Sasaki A, Masuda Y, et al. Vitamin D hormone inhibits osteoclastogenesis in vivo by decreasing the pool of osteoclast precursors in bone marrow. J Bone Miner Res. 2002;17:622-9. (Pubitemid 34246637)
78. Iwamoto J, Seki A, Takeda T, Sato Y, Yamada H, Yeh JK. Effect of risedronate on the cortical and cancellous bone mass and mechanical properties in ovariectomized rats:a comparison with the effects of alfacalcidol. J Nutr Sci Vitaminol. 2006;52:393-401. (Pubitemid 46292972)
79. Richy F, Deroisy R, Lecart MP, Hanssens L, Mawet A, Reginster JY. D-Hormone analog alfacalcidol: an update on its role in post-menopausal osteoporosis and rheumatoid arthritis management. Aging Clin Exp Res. 2005;17:133-42. (Pubitemid 41558122)
80. Schacht E, Richy F, Reginster JY. The therapeutic effect of alfacalcidol on bone strength, muscle metabolism and prevention of falls and fractures. J Musculoskelet Neuronal Interact. 2005;5:273-84. (Pubitemid 41684176)
81. Bischoff HA, Staehelin HB, Urscheler N, Ehrsam R, Vonthein R, Perrig-Chiello P, et al. Muscle strength in the elderly: its relation to vitamin D metabolites. Arch Phys Med Rehabil. 1999;80(1):54-8. (Pubitemid 29035822)
82. Dukas L, Staehelin HB, Schacht E, Bischoff HA. Better functional mobility in community-dwelling elderly is related to D-hormone serum levels and to a daily calcium intake. Nutr Health Aging. 2005;9(5):347-51. (Pubitemid 41499864)
83. Faulkner KA, Cauley JA, Zmuda JM, Landsittel DP, Newman AB, Studenski SA, et al. Higher 1.25-dihydroxyvitamin D3 concentrations associated with lower fall rates in older community-dwelling women. Osteoporos Int. 2006;17(9): 1318-28. (Pubitemid 44127318)
84. Sasaki H, Miyakoshi N, Kasukawa Y, Maekawa Y, Kamo K, Shimada Y. Effects of alfacalcidol on bone and skeletal muscle in glucocorticoid treated rats. J Bone Miner Res. 2008;23:427.
85. 2 vitamin D3 are detected only in the presence of a powerful antiresorptive. J Bone Miner Res. 2004;19:S483.
86. Bock O, Boerst H, Runge M, Schacht E, Kalbow M, Mazor Z, et al. Effects of a combined treatment with alfacalcidol and alendronate versus treatment with alendronate alone on BMD (DXA) at lumbar spine and total hip, and on peripheral fractures in postmenopausal women with osteoporosis or osteopenia, 3 year results. 2009; ASBMR 2009. Available from: http://www.asbmr.org/Meetings/Annual- Meeting/AbstractDetail.aspx?aid=80a55ed6-2877-4ccba217-c8b8b3c595ed
87. Ones K, Schacht E, Dukas L, Caglar N. Effects of combined treatment with alendronate and alfacalcidol on bone mineral density and bone turnover in postmenopausal osteoporosis: A two-years, randomized, multiarm, controlled trial. The Internet Journal of Epidemiology. 2007;4(1).
88. Frediani B, Allegri A, Bisogno S, Marcolongo R. Effects of combined treatment with calcitriol plus alendronate on bone mass and bone turnover in post-menopausal osteoporosis. Two years of continuous treatment. Clin Drug Invest. 1998;15:235-44.
89. Barone A, Giusti A, Pioli G, Girasole G, Razzano M, Pissonia M, et al. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial. J AmGeriatr Soc. 2007;55:752-7. (Pubitemid 46668979)
90. Gaal J, Bender T, Varga J, Horvath I, Kiss J, Somogyi P, et al. Overcoming resistance to bisphosphonates through the administration of alfacalcidol. Results of a 1 year open follow-up study. Rheumatol Int. 2009. doi: 10.1007/s00296-009-0892-9.
91. Miyakoshi N, Kasukawa Y, Kodama H, Noguchi H, Sasaki H, Kamo K, et al. Antifracture efficacy of combined treatment with alendronate and alfacalcidol for osteoporotic vertebrae in early-phase treatment: a preliminary report. Osteoporos Int. 2008;19(Suppl. 2):279.
92. Nevitt MC, Ettinger BE, Black DM, Stone K, Jamal SA, Ensrud K, et al. The association of radiographically detected vertebral fractures with back pain and function: a prospective study. Ann Intern Med. 1998;128:793-800 (Pubitemid 28267711)
93. Huang C, Ross PD, Wasnich RD. Vertebral fractures and other predictors of back pain among older women. J Bone Miner Res. 1996;11:1026-32. (Pubitemid 26200055)
94. Dukas LC, Schacht E, Mazor Z, Stahelin HB. A new significant and independent risk factor for falls in elderly men and women: a lowcreatinine clearance of less than 65 ml/ min. Osteoporos Int. 2005;16(3):332-8. (Pubitemid 40379434)
95. Ensrud KE, Lui LY, Taylor BC, Ishani A, Shlipak MG, Stone KL, et al.; for the Study of Osteoporotic Fractures Research Group. Renal Function and risk of hip and vertebral fractures in older women. Arch Intern Med. 2007;167:133-9.
96. Jassal SK, von Muhlen D, Barrett-Connor E. Measure of renal function, BMD, bone loss and osteoporotic fracture in older adults: the Rancho Bernardo Study. J Bone Miner Res. 2007;22:203-10. (Pubitemid 46167790)
97. Dukas L, Schacht E, Runge M, Ringe JD. Effect of a sixmonth therapy with alfacalcidol on muscle power and balance and the number of fallers and falls. Arzneimittelforschung. 2010;60(8):519-25.
98. Schacht E, Ringe JD. Alfacalcidol improves muscle power, muscle function and balance in elderly patients with reduced bone mass. Accepted for publication in: Rheumatol Int.
99. Dambacher MA. Praktische Osteologie. Stuttgart: Georg Thieme Verlag; 1982. p. 70-73.
100. Ringe JD, Farahmand P. Opioide und Osteoporose. Insuffiziente Schmerztherapie begünstigt Fortschreiten der Osteoporose. Arzneimitteltherapie. 2004;22:265-70.
101. Ringe JD, Dorst A, Faber H, Schacht E, Rahlfs VW. Superiority of alfacalcidol over plain vitamin D in the treatment of glucocorticoid-induced osteoporosis. Rheumatol Int. 2004;24:63-70. (Pubitemid 38388746)
102. Yang HI, Park KH, Lee BS, Choi YS, Cho SH, Kim HY, et al. Multifactorial effects of a combined alendronate and calcitriol agent (Maxmarvil. ) on bone and muscle strength in Korean postmenopausal women with osteopenia or osteoporosis. Menopause. 2009;16(6):1257-8.
103. Zhang Z. Effects of calcitriol on serum cytokines, bone markers, insulin and lipid concentrations in post-menopausal women with type II diabetes. Menopause. 2009;16(6):1258.
104. Leveille SG, Bean J, Ngo L, McMullen W, Guralik JM. The pathway from musculoskeletal pain to mobility difficulty in older disabled women. Pain. 2007;128:69-77. (Pubitemid 46216600)
105. Saito M, Shiraishi A, Ito M, Sakai S, Hayakawa N, Mihara M, et al. Comparison of effects of alfacalcidol and alendronate on mechanical properties and bone collagen cross-links of callus in the fracture repair rat model. Bone. 2010;46(4):1170-9.; doi: 10.1016/j.bone.2009.12.008.
106. Plotnikoff GA, Quigley JM. Prevalent of severe hypovitaminosis D in patients with persistent, nonspecific musculoskeletal pain. Mayo Clin Proc. 2003;78:1463-70.
107. Lewis PJ. Vitamin D deficiency may have role in chronic low back pain. Br Med J. 2005;331:109. (Pubitemid 40978794)
108. Holick MF.Vitamin D deficiency. N Engl J Med. 2007;357:266-81.
109. Hicks GE, Shardell M, Miller R, Bandinelli S, Guralnik J, Cherubini A, et al. Associations between vitamin D status and pain in older adults: the Invecchiare in Chianti Study. J AmGeriatr Soc. 2008;56 (5):785-91. (Pubitemid 351652383)
110. Atherton K, Berry DJ, Parsons T, Macfarlane GJ, Power C, Hyppönen E. Vitamin D and chronic widespread pain in a white middle-aged British population: evidence from a cross-sectional population survey. Ann Rheum Dis. 2009;68(6):817-22.
111. Venning G. Recent Developments in vitamin D deficiency and muscle weakness among elderly people. Br Med J. 2005;330:524-6. (Pubitemid 40343357)
112. Holick MF. Optimal vitamin D status for the prevention and treatment of osteoporosis. Drugs Aging. 2007;24(12):1017-29. (Pubitemid 350145410)
113. Lee P, Chen R. Vitamin D as an analgesic for patients with type II diabetes and neuropathic pain. Arch Intern Med. 2208;168:771-2.
114. Orimo H, Nakamura T, Shiraki M, Ohta H, Fukunaga M. Alendronate with alfacalcidol yields greater effectiveness than monotherapy with alendronate in postmenopausal elderly patients with osteoporosis: results from the Joint-02 randomized controlled trial. Osteoporosis Int . 2010; 21(Suppl):184.
115. Van Etten E, Branisteanu DD, Overbergh L, Bouillon R, Verstuyf A, Mathieu C. Combination of a 1.25-dihydroxyvitamin D3 analog and a bisphosphonate prevents experimental autoimmune encephalomyelitis and preserves bone. Bone. 2003;32:397-404. (Pubitemid 36407540)
116. Ott SM. Long-termsafety of bisphosphonates [editorial]. J Clin Endocrinol Metab. 2005;90(3):1897-9.
117. Ardine M, Generali D, Donadio M, Bonradi S, Scoletta M, Vandone AM, et al. Could the long-term persistence of low serum calcium levels and high serum parathyroid hormone levels during bisphosphonate treatment predispose metastatic breast cancer patients to undergo osteonecrosis of the jaw? Ann Oncol. 2006;17(8):1336-7.
118. Lesclous P, Najim SA, Carrel JP, Baroukh B, Lombardi T, Willi JP, et al. Bisphosphonate-associated osteonecrosis of the jaw: A key role of inflammation? Bone. 2009;45:843-52.
119. Hokugo A, Christensen R, Chung EM, Sung EC, Felsenfeld AL, Sayre JW, et al. Increased prevalence of bisphosphonate-related osteonecrosis of the jaw with vitamin D deficiency in rats. J Bone Miner Res. 2010;25(6):1337-49.
120. Ringe JD, van der Geest SA, Möller G. Importance of calcium co-medication in bisphosphonate therapy of osteoporosis: an approach to improving correct intake and drug adherence. Drugs Aging. 2006;23(7):569-78. (Pubitemid 44310548)
121. Ringe JD, Fardellone P, Kruse HP, Amling M, van der Geest SA, Möller G. Value of a new fixed-combination pack of bisphosphonate, calciumand vitamin D in the therapy of osteoporosis: results of two quantitative patient research studies. Drugs Aging. 2009;26(3):241-53.
122. Straube S, Moore RA, Derry S, McQuay J. Vitamin D and chronic pain. Pain. 2009;141:10-3.
123. Wicherts IS, van Schoor NM, Boeke AJP, Visser M, Deeg DJH, Smit J, et al. Vitamin D status predicts physical performance and its decline in older persons. J Clin Endocrinol Metab. 2007;92(6):2058-65. (Pubitemid 46997101)
124. Orimo H, Nakamura T, Ohta H, Fukunaga M, Hosoi T, Uemura Y et al. and A-TOP Research Group. Prevention of new osteoporotic fractures for postmenopausal women treated with the combination therapy (alendronate with alfacalcidol): The Japanese Osteoporosis Intervention Trial (JOINT-02). Osteoporos Int. 2010;21(5):S757.